These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 31405846)

  • 1.
    Yogev O; Almeida GS; Barker KT; George SL; Kwok C; Campbell J; Zarowiecki M; Kleftogiannis D; Smith LM; Hallsworth A; Berry P; Möcklinghoff T; Webber HT; Danielson LS; Buttery B; Calton EA; da Costa BM; Poon E; Jamin Y; Lise S; Veal GJ; Sebire N; Robinson SP; Anderson J; Chesler L
    Cancer Res; 2019 Oct; 79(20):5382-5393. PubMed ID: 31405846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
    Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA
    Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive MRI Native T
    Zormpas-Petridis K; Poon E; Clarke M; Jerome NP; Boult JKR; Blackledge MD; Carceller F; Koers A; Barone G; Pearson ADJ; Moreno L; Anderson J; Sebire N; McHugh K; Koh DM; Chesler L; Yuan Y; Robinson SP; Jamin Y
    Cancer Res; 2020 Aug; 80(16):3424-3435. PubMed ID: 32595135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.
    Hagemann S; Misiak D; Bell JL; Fuchs T; Lederer MI; Bley N; Hämmerle M; Ghazy E; Sippl W; Schulte JH; Hüttelmaier S
    Mol Cancer; 2023 May; 22(1):88. PubMed ID: 37246217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.
    Rasmuson A; Segerström L; Nethander M; Finnman J; Elfman LH; Javanmardi N; Nilsson S; Johnsen JI; Martinsson T; Kogner P
    PLoS One; 2012; 7(12):e51297. PubMed ID: 23284678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
    Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
    PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.
    Jamin Y; Tucker ER; Poon E; Popov S; Vaughan L; Boult JK; Webber H; Hallsworth A; Baker LC; Jones C; Koh DM; Pearson AD; Chesler L; Robinson SP
    Radiology; 2013 Jan; 266(1):130-40. PubMed ID: 23169794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice.
    Quarta C; Cantelli E; Nanni C; Ambrosini V; D'ambrosio D; Di Leo K; Angelucci S; Zagni F; Lodi F; Marengo M; Weiss WA; Pession A; Tonelli R; Fanti S
    Mol Imaging Biol; 2013 Apr; 15(2):194-202. PubMed ID: 22777578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Proteomics of Th-MYCN Transgenic Mice Reveals Aurora Kinase Inhibitor Altered Metabolic Pathways and Enhanced ACADM To Suppress Neuroblastoma Progression.
    Hsieh CH; Cheung CHY; Liu YL; Hou CL; Hsu CL; Huang CT; Yang TS; Chen SF; Chen CN; Hsu WM; Huang HC; Juan HF
    J Proteome Res; 2019 Nov; 18(11):3850-3866. PubMed ID: 31560547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.
    Terrile M; Bryan K; Vaughan L; Hallsworth A; Webber H; Chesler L; Stallings RL
    PLoS One; 2011; 6(12):e28356. PubMed ID: 22164278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.
    Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958555
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.
    Chen L; Esfandiari A; Reaves W; Vu A; Hogarty MD; Lunec J; Tweddle DA
    Int J Oncol; 2018 Mar; 52(3):967-977. PubMed ID: 29393340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.
    Decaesteker B; Denecker G; Van Neste C; Dolman EM; Van Loocke W; Gartlgruber M; Nunes C; De Vloed F; Depuydt P; Verboom K; Rombaut D; Loontiens S; De Wyn J; Kholosy WM; Koopmans B; Essing AHW; Herrmann C; Dreidax D; Durinck K; Deforce D; Van Nieuwerburgh F; Henssen A; Versteeg R; Boeva V; Schleiermacher G; van Nes J; Mestdagh P; Vanhauwaert S; Schulte JH; Westermann F; Molenaar JJ; De Preter K; Speleman F
    Nat Commun; 2018 Nov; 9(1):4866. PubMed ID: 30451831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
    Zhong ZY; Shi BJ; Zhou H; Wang WB
    J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk
    Wei JS; Kuznetsov IB; Zhang S; Song YK; Asgharzadeh S; Sindiri S; Wen X; Patidar R; Najaraj S; Walton A; Auvil JMG; Gerhard DS; Yuksel A; Catchpoole D; Hewitt SM; Sondel PM; Seeger R; Maris JM; Khan J
    Clin Cancer Res; 2018 Nov; 24(22):5673-5684. PubMed ID: 29784674
    [No Abstract]   [Full Text] [Related]  

  • 16. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.
    Blanc E; Goldschneider D; Ferrandis E; Barrois M; Le Roux G; Leonce S; Douc-Rasy S; Bénard J; Raguénez G
    Am J Pathol; 2003 Jul; 163(1):321-31. PubMed ID: 12819037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.
    Duffy DJ; Krstic A; Halasz M; Schwarzl T; Konietzny A; Iljin K; Higgins DG; Kolch W
    Genome Med; 2017 Feb; 9(1):15. PubMed ID: 28187790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
    Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M
    Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted expression of MYCN causes neuroblastoma in transgenic mice.
    Weiss WA; Aldape K; Mohapatra G; Feuerstein BG; Bishop JM
    EMBO J; 1997 Jun; 16(11):2985-95. PubMed ID: 9214616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
    Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
    Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.